Drug discovery and development for inflammatory diseases

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 2, 2004, Pages 151-163

  Edwards III, Carl K ^a,b,c  

^a Research Business Area Dermatology USA   (United States)

^b BAYER AG   (Germany)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

IL 1; Inflammation; Osteoarthritis (OA); Pro inflammatory cytokines; Psoriasis; Rheumatoid arthritis (RA); TNF

Indexed keywords

ASCOMYCIN; BMS 345541; CC 401; CORTICOSTEROID; CPG 7909; CYCLOSPORIN A; CYTOKINE; EDOBACOMAB; GAMMA INTERFERON; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; I KAPPA B KINASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 4; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUTRALIZING ANTIBODY; NPI 1302A 3; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PIMECROLIMUS; RECOMBINANT HEPATITIS B VACCINE; SCR 0265096; SP 60012; SPC 839; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAXIMMUNE;

ACUTE DISEASE; ARTICLE; BIOTECHNOLOGY; CHRONIC DISEASE; CIRCULATION; DRUG DESIGN; DRUG INDUSTRY; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; GENE OVEREXPRESSION; HOST RESISTANCE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; PATHOGENESIS; SIDE EFFECT; SKIN ATROPHY; TARGET ORGAN;

ANIMALS; AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION MEDIATORS; OSTEOARTHRITIS; TECHNOLOGY, PHARMACEUTICAL;

EID: 1842854534     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/eott.8.2.151.30245     Document Type: Article

References (23)

1. KALTHOFF FS, CHUNG J, STUETZ A: Pimecrolimus inhibits up-regulation of OX-40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dcndritic cells. Clin. Exp. Immunol. (2002) 130(1):85-92.
2. RAPPERSBERGER K, KOMAR M, EBELIN ME et al.: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J. Invest. Dermatol. (2002) 119(4):876-887.
3. BENNETT BL, SATOH Y, LEWIS AJ: JNK: a new therapeutic target for diabetes. Curr. Opin. Pharmacol. (2003) 3(4):420-425.
4. KORSTANJE C: Shifting attention from one cell type to another in dermatological research, but where are the new drugs? Curr. Opin. Investig. Drugs (2001) 2(5):624.
5. HOUSTON P, GOODMAN J, LEWIS A et al.: Homing markers for atherosclerosis: applications for drug delivery, gene delivery and vascular imaging. FEBS Lett. (2001) 492(1-2):73-77.
6. ASADULLAH K, STEERY W, STEPHANEK K et al.: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. (1998) 101(4):783-794.
7. ASADULLAH K, DOECKE WD, EBELING M et al.: Interleukin 10 treatment of psoriasis: clinical results of a Phase II trial. Arch. Dermatol. (1999) 135(2):187-192.
8. JUNG M, SABAT R, KRAETZSCHMAR J et al.: Expression profiling of IL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur. J. Immunol. (2004) 34(2):481-493.
9. ECONOMIDES AN, CARPENTER LR, RUDGE JS et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9(1):47-52.
10. DINARELLO CA: Setting the cytokine trap for autoimmunity. Nat. Med. (2003) 9(1):20-22.
11. EDWARDS CK III, MARTIN SW, SEELY J et al.: Design of PEGylated soluble tumor necrosis factor receptor Type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv. Drug Deliv. Rev. (2003) 55(10):1315-1336.
12. PALLADINO MA, BAHJAT FR, THEODORAKIS EA et al.: Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discov. (2003) 2(9):736-746.
13. LAM T, LING T, CHOWDHURY C et al.: Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents. Bioorg. Med. Chem. Lett. (2003) 13(19):3217-3221.
14. ONUFFER J, MCCARRICK MA, DUNNING L et al.: Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1. J. Immunol. (2003) 170(4):1910-1916.
15. BOZKURT B, TORRE-AMIONE G, WARREN MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation (2001) 103(8):1044-1047.
16. SLIFMAN NR, GERSHON SK, LEE JH et al.: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α-neutralizing agents. Arthritis Rheum. (2003) 48(2):319-324.
17. LEE JH, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum. (2002) 46(10):2565-2570.
18. NETEA MG, RADSTASKE T, JOOSTEN LA et al.: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arhritis Rheum. (2003) 48(7):1853-1857.
19. FRISHMAN JI, EDWARDS CK III, SONNENBERG MG, KOHNO T, COHEN AM, DINARELLO CA: Tumor necrosis factor (TNF)-α-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J. Infect. Dis. (2000) 182(6 ):1722-1730.
20. SCALLON B, CAI A, SOLOWSKI N et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. (2002) 301(2):418-426.
21. VAN DEVENTER SJ: Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology (2001) 121(5):1242-1246.
22. VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 124(7):1774-1785.
23. BOUWMEESTER T, BAUCH A, RUFFNER H et al.: A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat. Cell Biol. (2004) 6(2):97-105.